These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1689410)

  • 21. Cardiovascular pharmacology of ACC-9089--a novel, ultra-short-acting, beta-adrenergic receptor antagonist.
    Gorczynski RJ; Vuong A
    J Cardiovasc Pharmacol; 1984; 6(4):555-64. PubMed ID: 6206307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular effects of a novel calcium entry blocking and selective beta 1-adrenoceptor blocking agent, YM-16151-4, in anesthetized and conscious dogs.
    Uchida W; Shibasaki K; Asano M
    J Cardiovasc Pharmacol; 1992 Jan; 19(1):60-8. PubMed ID: 1375689
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Controlled beta-receptor blockade with esmolol and flestolol.
    Murthy VS; Frishman WH
    Pharmacotherapy; 1988; 8(3):168-82. PubMed ID: 2902602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical electrophysiology of flestolol, a potent ultra short-acting beta blocker.
    Swerdlow CD; Peterson J; Turlapaty P
    Am Heart J; 1986 Jan; 111(1):49-53. PubMed ID: 2868646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Downregulation of propranolol-sensitive beta-adrenoceptor signaling after inhibition of nitric oxide synthesis.
    Whalen EJ; Bates JN; Johnson AK; Lewis SJ
    Br J Pharmacol; 2006 Apr; 147(7):755-64. PubMed ID: 16474417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular pharmacology of ASL-8052, an ultra-short acting beta blocker.
    Murthy VS; Hwang TF; Zagar ME; Vollmer RR; Schmidt DH
    Eur J Pharmacol; 1983 Oct; 94(1-2):43-51. PubMed ID: 6140172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beta 1-selectivity of bisoprolol, a new beta-adrenoceptor antagonist, in anesthetized dogs and guinea pigs.
    Schliep HJ; Harting J
    J Cardiovasc Pharmacol; 1984; 6(6):1156-60. PubMed ID: 6084774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiohemodynamic effects of bopindolol in normotensive conscious dogs. A comparative study with pindolol.
    Ishibashi T; Mitomi A; Tatebe S; Imai S
    Arzneimittelforschung; 1989 Apr; 39(4):454-7. PubMed ID: 2568836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular effects of YM-16151-1 and its optical isomers: a novel calcium entry blocking and beta 1-adrenoceptor blocking agent.
    Uchida W; Shibasaki K; Asano M; Takenaka T
    Arch Int Pharmacodyn Ther; 1993; 321():30-40. PubMed ID: 8100704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mediation of the positive chronotropic effect of CGP 12177 and cyanopindolol in the pithed rat by atypical beta-adrenoceptors, different from beta 3-adrenoceptors.
    Malinowska B; Schlicker E
    Br J Pharmacol; 1996 Mar; 117(5):943-9. PubMed ID: 8851515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of the beta 2-adrenoceptor antagonist ICI 118,551 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man.
    Arnold JM; O'Connor PC; Riddell JG; Harron DW; Shanks RG; McDevitt DG
    Br J Clin Pharmacol; 1985 May; 19(5):619-30. PubMed ID: 2860915
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The effect of beta-receptor blockers on the isoprenaline-induced increase of heart muscle oxygen consumption].
    Liu GD; Yue WL
    Yao Xue Xue Bao; 1985 Mar; 20(3):209-210. PubMed ID: 2866658
    [No Abstract]   [Full Text] [Related]  

  • 33. Celiprolol: a positive inotropic beta-adrenoceptor blocking agent in conscious dogs.
    Nganele DM; DeLeonardis VM; Hintze TH
    Br J Pharmacol; 1988 Mar; 93(3):501-8. PubMed ID: 2897217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hemodynamic effects of orally administered carvedilol in healthy conscious dogs.
    Abbott JA; Broadstone RV; Ward DL; Pyle RL
    Am J Vet Res; 2005 Apr; 66(4):637-41. PubMed ID: 15900944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of flestolol on ventricular rate during atrial fibrillation in Wolff-Parkinson-White syndrome.
    Swerdlow CD; Peterson J; Liem LB
    Am J Cardiol; 1988 Jul; 62(1):78-82. PubMed ID: 2898208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of flestolol in man: preliminary data.
    Achari R; Hulse JD; Drissel D; Matier WL
    Br J Clin Pharmacol; 1985 Dec; 20(6):691-4. PubMed ID: 2868745
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of beta 1- and beta 2-adrenoceptor stimulation on hemodynamics in the anesthetized rat.
    Abdelrahman A; Tabrizchi R; Pang CC
    J Cardiovasc Pharmacol; 1990 May; 15(5):720-8. PubMed ID: 1692931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of beta-adrenoceptors mediating renin release produced by isoproterenol in conscious dogs.
    Himori N; Izumi A; Ishimori T
    Am J Physiol; 1980 May; 238(5):F387-93. PubMed ID: 6103674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular effects of YM430, a 1,4-dihydropyridine derivative with beta-adrenoceptor blocking activity, in dogs and rats.
    Shibasaki K; Uchida W; Takizawa K; Masuda N; Okazaki T; Inagaki O; Asano M; Takenaka T
    Biol Pharm Bull; 1997 Mar; 20(3):230-6. PubMed ID: 9084878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitation of the ultra short acting beta-adrenergic antagonist flestolol in blood by liquid chromatography.
    Moore P; Mai K; Lai CM
    J Pharm Sci; 1986 Apr; 75(4):424-6. PubMed ID: 2873234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.